Bipolar Disorder Drugs and Treatment Market
Market Insights on Bipolar Disorder Drugs and Treatment covering sales outlook, demand forecast & up-to-date key trends
Bipolar Disorder Drugs and Treatment Market By Drug Class (Mood Stabilizers, Anticonvulsants, Anti-psychotic Drugs, Anti-Depressant Drugs, and Anti-anxiety Drugs) & Region - Forecast 2022 - 2032
Bipolar Disorder Drugs and Treatment Market Outlook (2022-2032)
[350 Pages Report] The global bipolar disorder drugs and treatment market is forecasted to grow at a moderate CAGR of 3%, reaching nearly US$ 8.1 Bn by 2032 from US$ 5.7 Bn in 2021.
“Changing perspective about the importance of mental health treatments is anticipated to raise the sale of over the counter meds for bipolar disorder.”
As per the historical records, around 50 million people in the world suffer from some level of bipolar disorder and undergo some kind of depression in their early 20s.
According to the Global Burden of Disease report, the prevalence of bipolar disorder ranges from 0.3% to 1.2% among different regions. In recent years there has awareness about the disorder is growing shifting the perspective for it as a mental ailment creating a surge in the sale of natural bipolar medication.
With the changing perspective about mental health, the demand for natural bipolar meds or drugs is anticipated to grow by the patients suffering from such disease. A similar category of drugs, commonly known as bipolar depression treatment medication, is increasingly available in all parts of the world.
|
Attributes |
Details |
|
Bipolar Disorder Drugs and Treatment Market CAGR (2022-2032) |
3% |
|
Bipolar Disorder Drugs and Treatment Market (2027) |
US$ 7 Bn |
|
Bipolar Disorder Drugs and Treatment Market Attraction |
Support from the government organizations to increase awareness about the bipolar disorder is the major factor driving the bipolar drugs market. |
Let us know your requirement to get
100% FREE customization
What is the Covid-19 Impact on Bipolar Disorder Drugs and Treatment Market?
The market for bipolar disorder drugs and treatment was mildly hit by the Covid-19 pandemic restrictions. As there were widespread positive cases of patients infected by the novel Corona Virus, most of the resources and professionals of the healthcare sector were diverted towards the management of the Covid-19 menace.
Particularly the demand for medication for bipolar from the hospital and healthcare institutions dropped significantly. Surprisingly enough, the number of patients diagnosed with bipolar disorders increased significantly during the worldwide shutdown of the free movement of people.
This fact is hypothesized from the information of the increase in the volume of over the counter medicine for bipolar available during the pandemic times.
However, the market growth for prescribed drugs continued through the increase in bipolar meds online availability on e-commerce sites.
As the healthcare sector was kept as the most prioritized business activity, the drugs market recovered from the jolt of the pandemic within a few days. There were also some remarkable developments in the field of herbal medicine for bipolar disorder that has emerged as a successful niche for the bipolar disorder drugs and treatment market.
What is the Present Dynamics of the Global Bipolar Disorder Drugs and Treatment Market?
Bipolar disorders have been recognized as the 6th largest contributor in the total disabled person in the world by World Health Organizations or WHO. To mitigate the serious consequences, modern medical science has developed therapeutic drugs for its treatment that is available as bipolar over the counter meds in the drug stores.
Previously the consciousness and awareness about the remedial measures for any type of mental disorder were below the level resulting in less demand for good medicine for bipolar disorder produced by the pharmaceutical companies. However, in recent days with the growth in digital media, the acceptance of methods for treatment of bipolar is reflected in the huge growth in sales of over the counter meds for bipolar.
There is also some old age natural medication for bipolar disorder that is being actively researched and developed by pharmaceutical companies to augment their customer base. Many market players have succeeded in creating brand values by supplying mood stabilizers online to customers.
What are the Challenges Faced by Players in the Bipolar Disorder Drugs and Treatment Market?
The lithium (Li) element used in the production of anti mania drugs can cause anorexia if taken by an overdose. Also, the prolonged use of lithium can damage the effects of vasopressin hormone that can result in diabetes insipid, as sighted by many reports. This tact can hinder the wider adaptability of bipolar over the counter meds for disorder treatment as well.
As the typical age group for the emergence of any symptom of bipolar disorder is around 20 to 25 years, so it often gets neglected by the parents. This delays the tremendous procedure for bipolar disorders and reduces the effectiveness of natural bipolar meds, and hampers the value of the drug in the Market. Over the years, there are also a lot of generic medicines coming into the market in competition with well-established market chains of OTC mood stabilizer medications.
Addiction of the body to such types of drugs is another major concern for the use of such types of drugs by the patients. There is also very less number of anticonvulsant drugs approved for use as bipolar disorder medication over the counter that can hamper the rapid growth of the global market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystComparative View of Adjacent Bipolar Disorder Drugs and Treatment Market
|
Attributes |
Bipolar Disorder Drugs and Treatment Market |
Anti-mania Drugs Market |
Behavioral Health Market |
|
CAGR (2022 - 2032) |
3% |
10.2% |
7.6% |
|
Market Value (2027) |
US$ 7 Bn |
US$ 22 Bn |
US$ 42.3 Bn |
|
Growth Factor |
Growing Awareness about the effectiveness of drugs in treating bipolar disorders have increased its demand. |
By the support of government and international organizations mental disorder drugs are getting affordable and available in the market |
Alcohol overuse disorders are getting more common in recent times and requiring most of the behavioral health market drugs. |
|
Opportunity |
In Asia Pacific region the bipolar disorder cases are growing with the rapid urbanization with a great opportunity for market players. |
Innovative drugs discovered in the field of psychiatric disease have come up with new effective medicines for mental health. |
Emergency mental health services require sedatives as a precaution to deteriorating condition of patients growing the demand for it. |
|
Key Trends |
With the rationalization of drug regulations the sale of bipolar medicine on online platforms have increased. |
Increasing number of clinical tests is rising the count of mental disorder cases growing the demand for such drugs. |
With the starting of home based treatment services for behavioral health patients the sale of drugs on online platforms have increased. |
National Institute of Mental Health (NIMH) provides data for the number of people in USA developing bipolar disorder symptoms at approximately 10 million. By the support of government initiatives and dissemination of knowledge about the mental condition of such patients there has been an encouraging environment for their treatment through good medicine for bipolar disorder.
These drugs are also classified on the basis of mechanism they adopt to get into action. Selective serotonin reuptake inhibitor and serotonin norepinephrine reuptake inhibitors are the most prominent segments of liquid bipolar medication used for the bipolar disorder remedies.
The other segments in this category include tricyclic antidepressants, Menominee oxidase inhibitors, benzodiazepines, and beta blockers.
What is the Growth Outlook for the Bipolar Disorder Drugs and Treatment Market According to Different Class of Drugs?
The antipsychotic drugs are suitable to be used in combination therapy along with SSRI. Most healthcare professionals opt for antipsychotics drugs as it demonstrates better results than the other types of over the counter medicine for bipolar available in the market.
This segment is expected to contribute the major share of the revenue generated by the global bipolar disorder drugs and treatment market. It is also expected to grow at a higher CAGR of 2.8% than the other segments of the market over the forecast period. The antipsychotics drugs segment is estimated to be valued at US$ 3 Bn in the year 2027.
Anticonvulsant drugs are getting more adopted these days by physicians establishing a CAGR of 3.7% during the forecast years.
Names of some of the anticonvulsant drugs available in the form of best over the counter medicine for bipolar treatment include carbamazepine or Equetro, divalproex sodium or Depakote, lamotrigine or Lamictal, topiramate or Topamax and valproic acid, which is otherwise known as Depakene.
All of these anticonvulsant drugs currently account for 22% of the total global bipolar treatment market drugs and are expected to record a CAGR of 3.7% together, as mentioned before.
Mood stabilizer drugs help in controlling the swings in manic and depressive phases experienced by the patient by restoring the neurochemical balance.
A major percentage of customers for the mood stabilizer medications over the counter is present in developed economies such as the USA, Canada, Japan, and European countries of Spain, France, Germany, UK and Italy, commonly recognized as 8MM in the global bipolar disorder drugs and treatment market.
These regional markets together account for a market size of nearly US$ 874 Mn in 2021 and are projected to reach a valuation of US$ 1 bn by the end of the year 2027.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
What is the Performance of the Bipolar Disorder Drugs and Treatment Market?
The number of bipolar disorder cases in the North American region has been observed to be increasing day by day. The increase in disruption of daily lifestyle like insufficient sleep, wrong food habits or substance abuse and higher stress level in the youngster is the reason for the increasing sale of mood stabilizer medications over the counter, particularly in the USA.
On the record, North America accounted for more than 60% of the total revenue generated by the bipolar disorder drugs market globally. North America is predicted to retain its leading position during the forecast years, reaching a valuation of US$ 2.6 Bn in the year 2022.
Asia Pacific region is the significant region for the global bipolar disorder drugs and treatment market in terms of the highest growth rate in recent times.
A recent report published by World Health Organizations (WHO) ranked China and India as the top regions with patients diagnosed with anxieties, schizophrenia and bipolar disorders that will increase the sale of natural medications for bipolar disorder.
China, with a robust pharmaceutical manufacturing industry, is predicted to reach a valuation of more than US$ 500 Mn by the end of the year 2027. China is predicted to record a robust CAGR of 4.5% in the bipolar disorder drugs and treatment market over the forecast years.
Europe is estimated to grow at a CAGR less than the global average at 2.5% during the forecast period of 2022 to 2032. Strong policies to regulate the sale of over the counter medication for bipolar disorder is expected to limit the growth of bipolar disorder drugs and the treatment market in this region.
What are the Competitive Opportunities for the Global Bipolar Disorder Drugs and Treatment Market?
The main strategies adopted by the market players include the development of new drugs for bipolar disorder over the counter medication by investing in research and development (R&D) activities. Acquiring approvals for such over the counter medications is the most important step in gaining recognition for the newly developed medicines.
Expanding business activities by acquisition and merger of the locally established manufacturers supplying mood stabilizer medications over the counter in any area.
What are the Recent Developments in the Field of Bipolar Disorder Drugs and Treatment Market?
- For the treatment of bipolar I disorder among adults, Alkermes PLC developed a treatment drug by the name of LYBALVITM that is a combination of olanzapine and samidorphan. It received the approval of the US Food and Drug Administration (FDA) in June 2021, which will make it available as an over the counter medicine for bipolar treatment.
- The University of Illinois, which is present in the state of Chicago, launched a cell phone app by the name of BiAffect in 2018 that helps in tracking the manic disorder and depressive mood for the patients having bipolar disorder.
- Allergan PLC and Gedeon Richter PLC expanded the use of Vraylar, also known as cariprazine used in the treatment of the depressive condition in adults suffering from bipolar disorder after getting approval from the US Food and Drug Administration (FDA) by May 2019.
Key Players
- AbbVie Inc.
- Glaxo SmithKline (GSK)
- Eli, Lily and Company
- Janssen Pharmaceuticals
- Johnson & Johnson
- Astellas Pharma Inc
- Bristol Myers Squibb
- Gedeon Richter PLC.
- H. Lundbeck A/S
- Pfizer Inc.
- Novartis AG
- Otsuka Holdings Co. Ltd
- Validus Pharmaceuticals LLC.
Key Segments
By Drug Class:
- Mood Stabilizers
- Anticonvulsants
- Antipsychotic Drugs
- Antidepressant Drugs
- Anti-anxiety Drugs
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa (MEA)
Frequently Asked Questions
The bipolar disorder drugs and treatment market is estimated to record a CAGR of 3% during the forecast period.
The bipolar disorder drugs and treatment market is predicted to be valued at US$ 8.1 by the end of forecasted period of 2032.
The global bipolar disorder drugs and treatment market was valued at US$ 5.7 Bn in 2021.
North America accounts for the largest revenue share accounting more than 60% of the global bipolar disorder drugs and treatment market.
Asia Pacific region is predicted to witness the highest growth rate in the human bipolar disorder drugs and treatment market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032
5.3.1. Mood Stabilizers
5.3.2. Anti-convulsants
5.3.3. Anti-psychotic Drugs
5.3.4. Anti-depressant Drugs
5.3.5. Anti-anxiety Drugs
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032
6. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
6.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa
6.4. Market Attractiveness Analysis By Region
7. North America Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
7.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
7.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
7.2.1. By Country
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.2. By Drug Class
7.3. Market Attractiveness Analysis
7.3.1. By Country
7.3.2. By Drug Class
7.4. Key Takeaways
8. Latin America Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. Brazil
8.2.1.2. Mexico
8.2.1.3. Rest of Latin America
8.2.2. By Drug Class
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.4. Key Takeaways
9. Europe Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Germany
9.2.1.2. Italy
9.2.1.3. France
9.2.1.4. U.K.
9.2.1.5. Russia
9.2.1.6. BENELUX
9.2.1.7. Rest of Europe
9.2.2. By Drug Class
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.4. Key Takeaways
10. Asia Pacific Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. China
10.2.1.2. Japan
10.2.1.3. South Korea
10.2.1.4. Rest of Asia Pacific
10.2.2. By Drug Class
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.4. Key Takeaways
11. Middle East and Africa Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. GCC Countries
11.2.1.2. South Africa
11.2.1.3. Turkey
11.2.1.4. Rest of Middle East and Africa
11.2.2. By Drug Class
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.4. Key Takeaways
12. Key Countries Bipolar Disorder Drugs and Treatment Market Analysis
12.1. U.S.
12.1.1. Pricing Analysis
12.1.2. Market Share Analysis, 2021
12.1.2.1. By Drug Class
12.2. Canada
12.2.1. Pricing Analysis
12.2.2. Market Share Analysis, 2021
12.2.2.1. By Drug Class
12.3. Brazil
12.3.1. Pricing Analysis
12.3.2. Market Share Analysis, 2021
12.3.2.1. By Drug Class
12.4. Mexico
12.4.1. Pricing Analysis
12.4.2. Market Share Analysis, 2021
12.4.2.1. By Drug Class
12.5. Germany
12.5.1. Pricing Analysis
12.5.2. Market Share Analysis, 2021
12.5.2.1. By Drug Class
12.6. Italy
12.6.1. Pricing Analysis
12.6.2. Market Share Analysis, 2021
12.6.2.1. By Drug Class
12.7. France
12.7.1. Pricing Analysis
12.7.2. Market Share Analysis, 2021
12.7.2.1. By Drug Class
12.8. U.K.
12.8.1. Pricing Analysis
12.8.2. Market Share Analysis, 2021
12.8.2.1. By Drug Class
12.9. Russia
12.9.1. Pricing Analysis
12.9.2. Market Share Analysis, 2021
12.9.2.1. By Drug Class
12.10. BENELUX
12.10.1. Pricing Analysis
12.10.2. Market Share Analysis, 2021
12.10.2.1. By Drug Class
12.11. China
12.11.1. Pricing Analysis
12.11.2. Market Share Analysis, 2021
12.11.2.1. By Drug Class
12.12. Japan
12.12.1. Pricing Analysis
12.12.2. Market Share Analysis, 2021
12.12.2.1. By Drug Class
12.13. South Korea
12.13.1. Pricing Analysis
12.13.2. Market Share Analysis, 2021
12.13.2.1. By Drug Class
12.14. GCC Countries
12.14.1. Pricing Analysis
12.14.2. Market Share Analysis, 2021
12.14.2.1. By Drug Class
12.15. South Africa
12.15.1. Pricing Analysis
12.15.2. Market Share Analysis, 2021
12.15.2.1. By Drug Class
12.16. Turkey
12.16.1. Pricing Analysis
12.16.2. Market Share Analysis, 2021
12.16.2.1. By Drug Class
13. Market Structure Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Market Share Analysis of Top Players
13.3.1. By Regional
13.3.2. By Drug Class
14. Competition Analysis
14.1. Competition Deep Dive
14.1.1. AbbVie Inc.
14.1.1.1. Overview
14.1.1.2. Product Portfolio
14.1.1.3. Profitability by Market Segments
14.1.1.4. Sales Footprint
14.1.1.5. Strategy Overview
14.1.1.5.1. Marketing Strategy
14.1.2. Glaxo SmithKline (GSK)
14.1.2.1. Overview
14.1.2.2. Product Portfolio
14.1.2.3. Profitability by Market Segments
14.1.2.4. Sales Footprint
14.1.2.5. Strategy Overview
14.1.2.5.1. Marketing Strategy
14.1.3. Eli Lilly and company
14.1.3.1. Overview
14.1.3.2. Product Portfolio
14.1.3.3. Profitability by Market Segments
14.1.3.4. Sales Footprint
14.1.3.5. Strategy Overview
14.1.3.5.1. Marketing Strategy
14.1.4. Janssen Pharmaceuticals
14.1.4.1. Overview
14.1.4.2. Product Portfolio
14.1.4.3. Profitability by Market Segments
14.1.4.4. Sales Footprint
14.1.4.5. Strategy Overview
14.1.4.5.1. Marketing Strategy
14.1.5. Johnson & Johnson
14.1.5.1. Overview
14.1.5.2. Product Portfolio
14.1.5.3. Profitability by Market Segments
14.1.5.4. Sales Footprint
14.1.5.5. Strategy Overview
14.1.5.5.1. Marketing Strategy
14.1.6. Astellas Pharma Inc.
14.1.6.1. Overview
14.1.6.2. Product Portfolio
14.1.6.3. Profitability by Market Segments
14.1.6.4. Sales Footprint
14.1.6.5. Strategy Overview
14.1.6.5.1. Marketing Strategy
14.1.7. Bristol Myers Squibb
14.1.7.1. Overview
14.1.7.2. Product Portfolio
14.1.7.3. Profitability by Market Segments
14.1.7.4. Sales Footprint
14.1.7.5. Strategy Overview
14.1.7.5.1. Marketing Strategy
14.1.8. Gedeon Richter Plc.
14.1.8.1. Overview
14.1.8.2. Product Portfolio
14.1.8.3. Profitability by Market Segments
14.1.8.4. Sales Footprint
14.1.8.5. Strategy Overview
14.1.8.5.1. Marketing Strategy
14.1.9. H. Lundbeck A/S
14.1.9.1. Overview
14.1.9.2. Product Portfolio
14.1.9.3. Profitability by Market Segments
14.1.9.4. Sales Footprint
14.1.9.5. Strategy Overview
14.1.9.5.1. Marketing Strategy
14.1.10. Pfizer Inc.
14.1.10.1. Overview
14.1.10.2. Product Portfolio
14.1.10.3. Profitability by Market Segments
14.1.10.4. Sales Footprint
14.1.10.5. Strategy Overview
14.1.10.5.1. Marketing Strategy
14.1.11. Novartis AG
14.1.11.1. Overview
14.1.11.2. Product Portfolio
14.1.11.3. Profitability by Market Segments
14.1.11.4. Sales Footprint
14.1.11.5. Strategy Overview
14.1.11.5.1. Marketing Strategy
14.1.12. Otsuka Holdings Co. Ltd
14.1.12.1. Overview
14.1.12.2. Product Portfolio
14.1.12.3. Profitability by Market Segments
14.1.12.4. Sales Footprint
14.1.12.5. Strategy Overview
14.1.12.5.1. Marketing Strategy
14.1.13. Validus Pharmaceuticals LLC
14.1.13.1. Overview
14.1.13.2. Product Portfolio
14.1.13.3. Profitability by Market Segments
14.1.13.4. Sales Footprint
14.1.13.5. Strategy Overview
14.1.13.5.1. Marketing Strategy
15. Assumptions & Acronyms Used
16. Research Methodology
Let us know your requirement to get
100% FREE customization
Table 1: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 3: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 4: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 5: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 7: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 9: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 11: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 12: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFigure 1: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 2: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Region, 2022-2032
Figure 3: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 4: Global Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 5: Global Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 6: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 7: Global Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 8: Global Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 9: Global Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032
Figure 10: Global Bipolar Disorder Drugs and Treatment Market Attractiveness by Region, 2022-2032
Figure 11: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 12: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 13: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 14: North America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 15: North America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 16: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 17: North America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 18: North America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 19: North America Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032
Figure 20: North America Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032
Figure 21: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 22: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 23: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 24: Latin America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 25: Latin America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 26: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 27: Latin America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 28: Latin America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 29: Latin America Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032
Figure 30: Latin America Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032
Figure 31: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 32: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 33: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 34: Europe Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 35: Europe Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 36: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 37: Europe Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 38: Europe Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 39: Europe Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032
Figure 40: Europe Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032
Figure 41: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 42: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 43: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 44: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 45: Asia Pacific Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 46: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 47: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 48: Asia Pacific Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 49: Asia Pacific Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032
Figure 50: Asia Pacific Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032
Figure 51: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 52: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032
Figure 53: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 54: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 55: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 56: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 57: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 58: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 59: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032
Figure 60: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
